Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
22 12 2020
Historique:
pubmed: 4 12 2020
medline: 20 2 2021
entrez: 3 12 2020
Statut: ppublish

Résumé

Yellow fever (YF) is a mosquito-transmitted viral disease that causes tens of thousands of deaths each year despite the long-standing deployment of an effective vaccine. In its most severe form, YF manifests as a hemorrhagic fever that causes severe damage to visceral organs. Although coagulopathy is a defining feature of severe YF in humans, the mechanism by which it develops remains uncertain. Hepatocytes are a major target of yellow fever virus (YFV) infection, and the coagulopathy in severe YF has long been attributed to massive hepatocyte infection and destruction that results in a defect in clotting factor synthesis. However, when we analyzed blood from Brazilian patients with severe YF, we found high concentrations of plasma D-dimer, a fibrin split product, suggestive of a concurrent consumptive process. To define the relationship between coagulopathy and hepatocellular tropism, we compared infection and disease in

Identifiants

pubmed: 33268494
pii: 2014096117
doi: 10.1073/pnas.2014096117
pmc: PMC7768776
doi:

Substances chimiques

Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

32648-32656

Subventions

Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI073755
Pays : United States
Organisme : NIBIB NIH HHS
ID : T32 EB021955
Pays : United States
Organisme : NIAID NIH HHS
ID : R44 AI079898
Pays : United States

Informations de copyright

Copyright © 2020 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Competing interest statement: M.S.D. is a consultant for Inbios, Eli Lilly, Vir Biotechnology, NGM Biopharmaceuticals, and is on the Scientific Advisory Board of Moderna and Immunome. The Diamond laboratory has received funding unrelated to this project under sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions.

Références

J Virol. 2019 Jun 28;93(14):
pubmed: 31043530
Nat Biotechnol. 2007 Aug;25(8):903-10
pubmed: 17664939
J Gen Virol. 1986 Apr;67 ( Pt 4):631-7
pubmed: 3958694
Arch Virol. 1983;76(1):51-61
pubmed: 6860148
J Clin Virol. 2015 Mar;64:160-73
pubmed: 25453327
J Gen Virol. 2015 Jun;96(Pt 6):1328-1339
pubmed: 25646269
J Infect Dis. 1999 Feb;179 Suppl 1:S199-202
pubmed: 9988185
Br J Haematol. 1969 Nov;17(5):455-62
pubmed: 4981419
Am J Trop Med Hyg. 1982 May;31(3 Pt 1):548-55
pubmed: 6177259
Vet Clin North Am Small Anim Pract. 2017 May;47(3):601-615
pubmed: 28034472
Circ Res. 2005 Jun 24;96(12):1233-9
pubmed: 15920023
J Travel Med. 2019 Jun 11;26(5):
pubmed: 31180486
PLoS Pathog. 2009 Oct;5(10):e1000614
pubmed: 19816561
Lancet Glob Health. 2018 Mar;6(3):e270-e278
pubmed: 29398634
PLoS Pathog. 2007 Sep 14;3(9):1262-70
pubmed: 17941708
Am J Trop Med Hyg. 1981 Mar;30(2):431-43
pubmed: 7235133
Nat Commun. 2017 Mar 14;8:14781
pubmed: 28290449
J Travel Med. 2019 Jun 11;26(5):
pubmed: 31150098
Sci Rep. 2019 Dec 31;9(1):20418
pubmed: 31892699
Front Biosci (Landmark Ed). 2011 Jun 01;16(9):3196-215
pubmed: 21622229
Sci Rep. 2020 Feb 21;10(1):3180
pubmed: 32081931
Lancet Infect Dis. 2019 Jul;19(7):750-758
pubmed: 31104909
J Exp Med. 1937 May 31;65(6):787-800
pubmed: 19870634
Am J Clin Pathol. 1955 Feb;25(2):135-46
pubmed: 14349922
Genes (Basel). 2018 Jun 08;9(6):
pubmed: 29890711
Am J Trop Med Hyg. 2018 Jun;98(6):1833-1836
pubmed: 29611509
Trends Microbiol. 2018 Nov;26(11):913-928
pubmed: 29933925
Curr Opin Immunol. 2015 Oct;36:38-46
pubmed: 26163194
J Infect Dis. 2001 May 15;183(10):1431-6
pubmed: 11319679
J Virol. 2001 Nov;75(22):10912-22
pubmed: 11602731
Lancet. 2018 Dec 1;392(10162):2347
pubmed: 30527606
Clin Exp Immunol. 2002 Apr;128(1):163-8
pubmed: 11982604
Hepatology. 2005 Apr;41(4):847-56
pubmed: 15791625
J Virol. 2006 Dec;80(24):12149-59
pubmed: 17035317
Am J Trop Med Hyg. 2010 Jul;83(1):183-8
pubmed: 20595499
Science. 1930 Apr 4;71(1840):367
pubmed: 17731835
Emerg Microbes Infect. 2016 Jul 13;5(7):e69
pubmed: 27406389
Virology. 2005 Nov 25;342(2):167-76
pubmed: 16150475
Virus Res. 2013 Aug;175(2):155-9
pubmed: 23639427
Lancet Infect Dis. 2017 Nov;17(11):1209-1217
pubmed: 28822780
NPJ Vaccines. 2018 Jan 23;3:5
pubmed: 29387474
PLoS One. 2012;7(9):e41707
pubmed: 23028428
J Infect Dis. 2014 Aug 15;210(4):558-66
pubmed: 24526742
Virology. 2011 Mar 30;412(1):188-95
pubmed: 21277609
J Exp Med. 1931 Sep 30;54(4):533-55
pubmed: 19869938
Nature. 2019 Aug;572(7768):199-204
pubmed: 31292543
Virology. 2003 Sep 30;314(2):662-70
pubmed: 14554093
Am J Trop Med Hyg. 1982 Jul;31(4):830-6
pubmed: 6285749
Am J Trop Med Hyg. 2006 Jun;74(6):1084-9
pubmed: 16760525
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3295
pubmed: 25412185
Adv Virus Res. 2003;60:343-95
pubmed: 14689698
J Gen Virol. 1996 Jun;77 ( Pt 6):1277-85
pubmed: 8683217
Thromb Res. 2011 Aug;128(2):103-16
pubmed: 21215993
J Thromb Haemost. 2007 Apr;5(4):670-9
pubmed: 17403201
Rev Med Virol. 2008 Sep-Oct;18(5):331-46
pubmed: 18615782
J Infect Dis. 2003 Dec 1;188(11):1618-29
pubmed: 14639531
J Virol. 1996 Apr;70(4):2208-14
pubmed: 8642644
J Gen Virol. 2011 Oct;92(Pt 10):2262-2271
pubmed: 21697351
Appl Microbiol. 1973 Apr;25(4):539-44
pubmed: 4633476

Auteurs

Adam L Bailey (AL)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110; adam.bailey@wustl.edu diamond@wusm.wustl.edu.

Liang-I Kang (LI)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110.

Luiz Gonzaga Francisco de Assis Barros D'Elia Zanella (LGF)

Division of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, Sao Paulo, Brazil 01246 903.
State Civil Servant's Hospital, São Paulo, Brazil 04028-000.

Cássia G T Silveira (CGT)

Division of Clinical Immunology and Allergy, School of Medicine, University of São Paulo, Sao Paulo, Brazil 01246 903.

Yeh-Li Ho (YL)

Department of Infectious and Parasitic Diseases, School of Medicine, University of São Paulo, Sao Paulo, Brazil 01246 903.

Lander Foquet (L)

Yecuris Corporation, Tualatin, OR 97062.

Greg Bial (G)

Yecuris Corporation, Tualatin, OR 97062.

Broc T McCune (BT)

Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.

Amaro Nunes Duarte-Neto (AN)

Department of Pathology, Clinical Hospital, School of Medicine, University of São Paulo, Sao Paulo, Brazil 01246 903.

Archana Thomas (A)

Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006.

Hans-Peter Raué (HP)

Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006.

Kathleen Byrnes (K)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110.

Esper G Kallas (EG)

Department of Infectious and Parasitic Diseases, School of Medicine, University of São Paulo, Sao Paulo, Brazil 01246 903.

Mark K Slifka (MK)

Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006.

Michael S Diamond (MS)

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110; adam.bailey@wustl.edu diamond@wusm.wustl.edu.
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110.
The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH